Decoy Therapeutics (DCOY) FCF Margin (2016 - 2026)
Decoy Therapeutics (DCOY) posted quarterly FCF Margin of 555.63% for Q2 2021, down 35642.0% year-over-year from N/an in Q2 2020, and down 158.92% quarter-over-quarter from 214.59% in Q1 2021.
Decoy Therapeutics (DCOY) FCF Margin (2016 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported FCF Margin for 6 consecutive years, with 555.63% the latest figure, recorded in Q2 2021.
- In Q2 2021, FCF Margin fell 35642.0% year-over-year to 555.63%; the TTM figure through Mar 2022 stood at 1924.83% (down 175114.0% YoY), while the FY2021 annual figure was 554.29%, down 35709.0% from the prior year.
- FCF Margin retreated to 555.63% in Q2 2021 per DCOY's latest filing, from 214.59% in the prior quarter.
- Across five years, FCF Margin topped out at 4574.68% in Q3 2018 and bottomed at 5270.68% in Q1 2018.
- Historically, FCF Margin has averaged 881.97% across 5 years, with a median of 306.17% in 2020.
- Annual changes were most pronounced in 2018 — FCF Margin soared 649266 bps — and 2019, when it sank 520807 bps.
- Decoy Therapeutics' FCF Margin stood at 2097.95% in 2017, then surged by 111 bps to 237.66% in 2018, then sank by 207 bps to 253.83% in 2019, then jumped by 63 bps to 92.87% in 2020, then sank by 498 bps to 555.63% in 2021.
- Business Quant data shows DCOY's FCF Margin at 555.63% in Q2 2021, 214.59% in Q1 2021, and 92.87% in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - | -1,165.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,165.06% |
| Jun 30, 2021 | -555.63% |
| Mar 31, 2021 | -214.59% |
| Dec 31, 2020 | -92.87% |
| Sep 30, 2020 | -199.75% |
| Jun 30, 2020 | -199.21% |
| Mar 31, 2020 | -327.32% |
| Dec 31, 2019 | -253.83% |
| Sep 30, 2019 | -633.39% |
| Jun 30, 2019 | -171.14% |
| Mar 31, 2019 | -285.02% |
| Dec 31, 2018 | 237.66% |
| Sep 30, 2018 | 4,574.68% |
| Jun 30, 2018 | -3,362.68% |
| Mar 31, 2018 | -5,270.68% |
| Dec 31, 2017 | -2,097.95% |
| Sep 30, 2017 | -1,917.98% |
| Jun 30, 2017 | -1,705.26% |
| Mar 31, 2017 | -3,400.47% |
| Dec 31, 2016 | -2,011.20% |